Following an extensive review of its manufacturing
network globally, Pfizer Inc (“Pfizer”) has taken a
decision to consolidate its manufacturing operations. In support of this program, PharmaBioSource is currently working with Wyeth Whitehall Pharmaceuticals
LLC (“WWP”), a subsidiary of Pfizer, on the divestiture of its Puerto Rico based Guayama Pharmaceutical Dosage Form Manufacturing site.
Project Guayama provides an opportunity to acquire
a state of the art, fully operational and licensed
pharmaceutical dosage form manufacturing site
encompassing the following operations:
- Extensive and diverse oral products manufacturing capabilities, including both wet and dry granulation, liquid product formulation, tableting and encapsulation, spheroids manufacturing and tablet coating producing a broad range of products, including products requiring high containment, oral contraceptives, DEA controlled substances and a variety of smaller volume specialty products.
- Modern packaging facilities including solid dosage bottle packaging and blister packaging with integrated cartoning, including hospital unit dose capabilities.
- Laboratory and Support Facilities: Modern well equipped laboratories (providing extensive technical process development and new product introduction services) in addition to substantial warehousing facilities and normal support services including utilities, waste water treatment, and administration offices within the Facility.
The original building was built in 1966. There are two major operations at the site — Pfizer Pharmaceuticals and Pfizer Consumer Health. Some of the infrastructure is shared by the plants, and the system of allocations for the distribution of infrastructure cost is well documented.
The site was first operated by American Home Products in 1983. The main building was commissioned in 1984. In 1999 there was a management integration of Pharmaceutical and Consumer facilities which was desegregated in 2003. In 2000 the Generics exited the site. Also in 1990 a suppositories plant was added. Over the years the plant has been expanded for introduction of new products. In 2009 the PAT technology platform was approved by the FDA.